Randomized adjuvant therapy trials in melanoma: surgical and systemic.

摘要: The utility of adjuvant surgical procedures in the management primary melanomas has been evaluated a large number phase III randomized trials. These trials have shown that wide margins, elective lymph node dissection, sentinel (SLN) biopsy, and prophylactic isolated limb perfusion (ILP) do not improve survival but may locoregional control. Based on claim providing benefit, these cannot be considered standard care routine melanoma. Regarding role SLN biopsy it must stated this procedure provides best information prognosis us with an important tool to stratify for study more homogeneous patient populations evaluate systemic therapies therapy remains marginal as result fact lack effective drugs stage IV disease is reflected by II-III Thus far, chemotherapeutic drugs, immunostimulants, various vaccines all failed. Interferon (IFN) effect relapse-free overall survival. its impact judged many too small care. population patients can benefit from IFN needs better defined identifying new biomarkers genomic proteomic studies, which are ongoing.